RxDoctor Payments Data

Dana Garrett, APRN

Family · Campbellsville, KYNPI 1245842566

Payments from drug & device makers

$1,169in general payments, 2019–2025

Across 74 payments — averaging $15.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$334
  • Novo Nordisk$150
  • Amgen$128
  • GSK$83
  • Johnson & Johnson$64
  • AstraZeneca$60
  • plus $350 from 14 others

What the payments were for

  • Food & beverage$1,15399%
  • Education$161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,169 in reported general payments places this provider in the 65th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$36,094
Medicare patients
160
Services billed
557

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide61$64,258
EliquisApixaban60$54,477
JardianceEmpagliflozin61$52,378
FarxigaDapagliflozin Propanediol56$48,874
JanuviaSitagliptin Phosphate34$28,138
XareltoRivaroxaban29$27,940
MounjaroTirzepatide27$27,356
Breztri AerosphereBudesonide/Glycopyr/Formoterol31$23,368
RybelsusSemaglutide14$18,157
Breo ElliptaFluticasone/Vilanterol48$17,915
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$16,530
Nurtec OdtRimegepant Sulfate11$10,791
Spiriva RespimatTiotropium Bromide19$9,837
EntrestoSacubitril/Valsartan13$9,346
VascepaIcosapent Ethyl14$8,715

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$150$82,41575 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$60$76,558107 claims
PfizerEliquis, Nurtec Odt$24$65,26871 claims
Boehringer IngelheimJardiance, Spiriva Respimat$14$62,21480 claims
GSKBreo Ellipta, Trelegy Ellipta$83$34,44665 claims
MerckJanuvia$25$28,13834 claims
Johnson & JohnsonXarelto$64$27,94029 claims
Lilly USA, LLCMounjaro$334$27,35627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,374 family providers in Kentucky.

Other family in Campbellsville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →